Voyager Therapeutics (VYGR) director receives 30,000 stock options grant

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of 3.43 per share and expire on June 9, 2036.

The award was issued under Voyager’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholder meeting, if he continues serving as a director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Higgins Michael J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 30,000 options Exercise price: 3.43 per share Expiration date: June 9, 2036 +1 more

4 metrics

Options granted 30,000 options Stock option grant to director on June 9, 2026

Exercise price 3.43 per share Exercise price for 30,000 option shares

Expiration date June 9, 2036 Option expiration for 30,000 granted options

Total derivative holdings after grant 30,000 options Total stock options held following this transaction

Key Terms

Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2025 Stock Incentive Plan financial

"issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."

director compensation policy financial

"in accordance with its director compensation policy"

vesting commencement date financial

"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/11/2026 - 04:03 PM Accepted by SEC EDGAR 06/11/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higgins Michael J

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.43	06/09/2026		A		30,000		(1)	06/09/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Michael J. Higgins	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Michael J. Higgins report in this Voyager Therapeutics (VYGR) Form 4?

Michael J. Higgins reported receiving a stock option grant for 30,000 Voyager Therapeutics common shares. The award is a director compensation grant under the 2025 Stock Incentive Plan, not an open-market purchase, and is exercisable at 3.43 per share until June 9, 2036.

How many Voyager Therapeutics (VYGR) options did Michael J. Higgins receive and at what price?

He received options covering 30,000 shares of Voyager Therapeutics common stock at an exercise price of 3.43 per share. These options give him the right, but not the obligation, to buy those shares at that price before their June 9, 2036 expiration.

What is the vesting schedule for Michael J. Higgins’ Voyager Therapeutics (VYGR) option grant?

All 30,000 option shares vest in a single tranche on the earlier of one year from the grant date or the next annual stockholder meeting. Vesting is conditional on Michael J. Higgins continuing to serve as a director through the applicable vesting date.

Is Michael J. Higgins’ Voyager Therapeutics (VYGR) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. Michael J. Higgins received 30,000 stock options for director service, with zero-cost grant on the transaction date and an exercise price of 3.43 per share, issued under the 2025 Stock Incentive Plan.

When do Michael J. Higgins’ Voyager Therapeutics (VYGR) stock options expire?

The options expire on June 9, 2036, giving him over a decade to exercise them after vesting. After that expiration date, any unexercised options become worthless and no longer provide the right to buy Voyager Therapeutics common shares.

How many Voyager Therapeutics (VYGR) derivative securities does Michael J. Higgins hold after this Form 4 transaction?

Following this grant, he holds 30,000 stock options as reported in the filing. These represent rights to acquire Voyager Therapeutics common stock at 3.43 per share, subject to the vesting terms and the June 9, 2036 expiration date.